The 2022 Hormone Therapy Position Statement (The Menopause Society)

Tier 1: Established: peer-reviewed research or government health authority
Publisher: The Menopause Society (formerly the North American Menopause Society) · Published: September 12, 2026 · Accessed: September 12, 2026

Visit the source ↗

Claims this source supports

• Different hormone therapy regimens may be associated with increased breast density, which may obscure mammographic interpretation, leading to more mammograms or more breast biopsies and a potential delay in breast cancer diagnosis. (Level II)
• Transdermal hormone therapy has not been associated with VTE risk in observational studies; limited observational data and a systematic review suggest less risk with transdermal hormone therapy than oral, although comparative randomized trial data are lacking.
• Lower doses of oral estrogen may confer less risk of VTE than higher doses, but comparative randomized trial data are lacking.
• Hormone therapy does not need to be routinely discontinued in women aged older than 60 or 65 years. (Level III)